The central theory behind AOD-9604s action revolves around its ability to enhance the breakdown of fats (lipolysis) while reducing the formation of new fat (lipogenesis)
However, although weight loss was observed in some studies, it did not occur in all studies (2)
BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
7d), indicating a lower response to FMD in comparison to patients carrying the R72 variant
They should have experience working with pregnant patients and understand the unique considerations of pregnancy physiology
